Antibodies may offer protection against tuberculosis
Despite being one of the body’s first lines of defense against infection, the role of antibodies in tuberculosis (TB) has gone largely unstudied.
Now, by harnessing a unique technology for rapidly analysing human antibodies, a team of researchers led by Harvard T.H. Chan School of Public Health and the Ragon Institute of MGH, MIT, and Harvard University has uncovered key differences in antibodies isolated from different groups of TB patients—findings that could spur new diagnostic tools and open a new scientific path towards an effective TB vaccine.
“Our work shatters some long-standing paradigms on TB,” explains co-senior author Sarah Fortune, professor of immunology and infectious diseases at Harvard Chan School and director of TB research at the Ragon Institute. “That means we’ll need to think differently about how the body develops natural immunity to the infection and how effective vaccines should be engineered.”
About a third of the world’s population carries the bacteria that cause TB, known as Mycobacterium tuberculosis or Mtb. In 2014, nearly 10 million people worldwide became newly infected with Mtb and 1.5 million died. Although there are drugs that can treat the infection, drug-resistance is a pervasive problem and the most potent tool for long-term TB control—a vaccine—remains an elusive goal.
For decades, scientists have probed the roles of different immune cells in the body, mainly T-cells, in fighting off TB, but relatively little attention has been paid to another key form of immune defense: Y-shaped proteins known as antibodies. Fortune and her colleagues set out to answer a couple simple questions about antibodies in TB: First, are they different in people who are actively sick with TB versus those who can control the infection? If so, do those differences simply reflect disease state or do they play a functional role in shaping the course of TB infection?
Notably, studies of other infectious diseases have recently shown that antibodies exert an array of important functions, via the targets they recognize (using their forked front ends) and the signals they send (through their tails, which can bind to receptors on cells’ surfaces). For example, an innovative method for studying antibodies in a comprehensive, unbiased way shed new light on their roles in HIV. The approach, known as systems serology and pioneered by co-senior author Galit Alter and her colleagues at Massachusetts General Hospital and the Ragon Institute, provided a powerful tool for probing the biology of TB.
Fortune, Galit, and their colleagues teamed up with clinical researchers Cheryl Day of Emory University and Blanca Restrepo of the University of Texas in Houston, who contributed patient samples collected from two groups of TB patients: those with so-called latent infection, who are able to naturally control TB, and those with active disease, who lack such control. “The real power of this collaboration is that it allowed us to apply cutting-edge immunological tools to TB,” said Fortune.
By analysing antibodies from the two TB patient groups and comparing them to each other, the Ragon-Harvard Chan School team was able to home in on some key differences. Although latently infected patients had lower overall levels of antibodies compared to those with active disease, their antibodies carried distinct molecular modifications—specifically unique sugar groups, called digalactose. On its own, the result has important implications because it could lay the foundation for a rapid diagnostic tool that distinguishes patients with active TB from those without.
But these sugary modifications are more than mere decorations; they also appear to boost the antibodies’ power to activate the immune system and propel Mtb-infected cells to kill the bacteria. Although these findings represent an important first step in unlocking the role of antibodies in TB infection, much more work is needed to understand the mechanisms through which these antibodies exert their differential effects.
Even still, the work opens up a tantalizing possibility. “One of the long-standing challenges in generating a TB vaccine is that we don’t really know how to build a vaccine that generates a robust T-cell response,” explains Fortune. “But now, with our findings suggesting an important role for antibodies, it casts light on a path toward TB vaccine development that is much more straightforward. That’s incredibly exciting.”
Subscribe
If you enjoyed this article, subscribe to receive more just like it.
